ASPARLAS SIDE EFFECTS
- Generic Name: calaspargase pegol-mknl injection
- Brand Name: Asparlas
- Drug Class: Enzymes, Oncology
SIDE EFFECTS
The following clinically significant adverse reactions are described in greater detail in other sections of the labeling:
- Hypersensitivity.
- Pancreatic Toxicity.
- Thrombosis.
- Hemorrhage.
- Hepatotoxicity.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of ASPARLAS was investigated in Study DFCI 11-001, an open-label, randomized, active-controlled multicenter clinical trial that treated 237 children and adolescents with newly-diagnosed ALL or lymphoblastic lymphoma, with ASPARLAS 2,500 U/m2 (n=118) or pegaspargase 2,500 U/m2 (n=119) as part of a Dana Farber Cancer Institute (DFCI) ALL Consortium backbone therapy. The median age on enrollment was 5 years (range, 1-20) years. The majority of patients were male (62%) and white (70%). Most patients were considered standard risk (SR, 59%) and had B-cell lineage ALL (87%).
The median number of doses during the study was 11 doses for ASPARLAS (administered every three weeks) and 16 doses for pegaspargase (administered every two weeks). The median duration of exposure was 8 months for both ASPARLAS and pegaspargase.
There was 1 fatal adverse reaction (multi-organ failure in the setting of chronic pancreatitis associated with a pancreatic pseudocyst).
Table 1 summarizes the incidence of selected Grades ≥3 adverse reactions that occurred in 2 or more patients receiving ASPARLAS. Because not all grade 1 and 2 adverse reactions were collected prospectively, only grade 3 and 4 adverse events are presented in Table 2.
Table 1: Selected Grades ≥ 3 Adverse Reactions in Patients Receiving ASPARLAS With Multi- Agent Chemotherapy (Study DFCI 11-001)*
| Adverse Reaction† | ASPARLAS 2,500 U/m2 N=118 |
Pegaspargase 2,500 U/m2 N=119 |
| Grades ≥3 n (%)§ |
Grades ≥3 n (%)§ |
|
| Elevated transaminase | 61 (52) | 79 (66) |
| Bilirubin increased | 24 (20) | 30 (25) |
| Pancreatitis | 21 (18) | 29 (24) |
| Abnormal clotting studies | 17 (14) | 25 (21) |
| Diarrhea | 10 (9) | 6 (5) |
| Hypersensitivity | 9 (8) | 8 (7) |
| Embolic and thrombotic events | 9 (8) | 10 (8) |
| Sepsis | 6 (5) | 7 (6) |
| Dyspnea | 5 (4) | 1 (1) |
| Hemorrhages | 5 (4) | 5 (4) |
| Fungal infection | 4 (3) | 3 (3) |
| Pneumonia | 4 (3) | 8 (7) |
| Arrhythmia | 2 (2) | 1 (1) |
| Cardiac failure | 2 (2) | 1 (1) |
| * ASPARLAS or pegaspargase were administered as a component of multi-agent chemotherapy regimens. † Grouped terms: Elevated transaminase: Alanine aminotransferase increased, Aspartate aminotransferase increased, Transaminases increased; Bilirubin increased: Bilirubin conjugated increased, Blood bilirubin increased; Pancreatitis: Amylase increased, Lipase increased, Pancreatic necrosis, Pancreatitis, Pancreatitis relapsing; Abnormal clotting studies: Activated partial thromboplastin time prolonged, Blood fibrinogen decreased; Diarrhea: Colitis, Diarrhea, Enterocolitis, Neutropenic colitis; Hypersensitivity: Anaphylactic reaction, Drug hypersensitivity, Hypersensitivity; Embolic and thrombotic events SMQ: Device related thrombosis, Disseminated intravascular coagulation, Embolism, Intracardiac thrombus, Intracranial venous sinus thrombosis, Pulmonary embolism, Superior sagittal sinus thrombosis, Thrombosis in device, Venous thrombosis, Venous thrombosis limb; Sepsis: Bacterial sepsis, Sepsis; Dyspnea: Hypoxia, Respiratory failure; Hemorrhages SMQ (excludes laboratory terms): Disseminated intravascular coagulation, Epistaxis, Hematoma, Hemorrhage intracranial, Melena, Esophageal ulcer hemorrhage, Small intestinal hemorrhage, Upper gastrointestinal hemorrhage; Fungal infection: Fungal infection, Hepatic infection fungal, Respiratory tract infection fungal, Splenic infection fungal, Systemic candida; Pneumonia: Lung infection, Pneumonia, Pneumonitis; Arrhythmia: Atrioventricular block complete, Sinus tachycardia, Ventricular arrhythmia; Cardiac failure: Ejection fraction decreased, Left ventricular dysfunction. § Grading is based on the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. |
||
In the subgroup of patients with B-cell lineage ALL, the complete remission rate in the ASPARLAS arm was 98% (95/97), compared to 99% in the pegaspargase arm; the Kaplan-Meier estimates of overall survival of the treatment arms were comparable.
Study AALL07P4
The safety of ASPARLAS was also evaluated in Study AALL07P4, an open-label, randomized, active-controlled, multicenter clinical trial that treated patients with newly-diagnosed high-risk B-precursor ALL using ASPARLAS 2,500 U/m2 (n=43) or 2,100 U/m2 (n=68), or pegaspargase 2,500 U/m2 (n=52), as a component of an augmented Berlin-Frankfurt-Münster (BFM) therapy regimen. The median age was 11 years (range 1 to 26 years); the median duration of exposure was 7 months for both ASPARLAS and pegaspargase. In this study, the induction mortality of patients treated with ASPARLAS was 2.8% (3 out of 111); there were no induction deaths among 52 patients treated with pegaspargase.
SRC: NLM .